Nuvectis Pharma, Inc. (NVCT)Healthcare | Biotechnology | Fort Lee, United States | NasdaqCM
8.90 USD
+0.55
(6.587%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.80 -0.10 (-0.100%) ⇩ (April 17, 2026, 6:46 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:31 p.m. EDT
NVCT is a highly volatile stock with a low market cap and negative earnings, indicating a high-risk profile. The recent price action shows a downward trend, but there is some recent upward movement. The stock has no dividend history, making it unattractive for dividend-focused investors. The options activity indicates mixed sentiment, with some speculation of upward movement but also caution. Given the high risk and negative fundamentals, it is not advisable for most investors to consider this stock unless they are willing to take on significant risk. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.061100 |
| AutoETS | 0.064948 |
| AutoTheta | 0.065639 |
| AutoARIMA | 0.078652 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.397 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 235,776,160 |
| Forward P/E | -9.27 |
| Beta | -0.21 |
| Website | https://www.nuvectis.com |
As of April 11, 2026, 1:31 p.m. EDT: Options speculators are showing mixed signals. For the April 17 expiration, there is significant open interest in both calls and puts, with ATM strikes having high IV, indicating uncertainty. The presence of top OI at higher strikes suggests some speculation of potential upward movement, but the high IV on puts indicates caution. For the July 17 expiration, the focus is on ATM calls, with higher IV on puts, suggesting a bearish sentiment. The October 16 expiration shows low activity, with minimal open interest in puts, which could indicate limited bearish sentiment. Overall, the options activity suggests a cautious approach with some potential for upward movement, but the market is uncertain.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.001199007 |
| Address1 | 1 Bridge Plaza |
| Address2 | 2nd Floor, Suite 275 |
| All Time High | 20.92 |
| All Time Low | 3.08 |
| Ask | 8.97 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 48,100 |
| Average Daily Volume3 Month | 57,293 |
| Average Volume | 57,293 |
| Average Volume10Days | 48,100 |
| Beta | -0.211 |
| Bid | 8.76 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 0.717 |
| City | Fort Lee |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.9 |
| Current Ratio | 2.385 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 8.92 |
| Day Low | 8.33 |
| Display Name | Nuvectis Pharma |
| Earnings Timestamp | 1,770,816,600 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 204,142,144 |
| Eps Forward | -0.96 |
| Eps Trailing Twelve Months | -1.32 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.5088 |
| Fifty Day Average Change | 0.39120007 |
| Fifty Day Average Change Percent | 0.045975942 |
| Fifty Two Week Change Percent | 0.1199007 |
| Fifty Two Week High | 11.52 |
| Fifty Two Week High Change | -2.6200008 |
| Fifty Two Week High Change Percent | -0.22743063 |
| Fifty Two Week Low | 5.55 |
| Fifty Two Week Low Change | 3.3499994 |
| Fifty Two Week Low Change Percent | 0.6036035 |
| Fifty Two Week Range | 5.55 - 11.52 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,643,985,000,000 |
| Float Shares | 15,438,834 |
| Forward Eps | -0.96 |
| Forward P E | -9.270833 |
| Free Cashflow | -6,832,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.41587 |
| Held Percent Institutions | 0.17152001 |
| Implied Shares Outstanding | 26,491,703 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,022-02-04 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. |
| Long Name | Nuvectis Pharma, Inc. |
| Market | us_market |
| Market Cap | 235,776,160 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1679395234 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -28,871,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 235,908,606 |
| Number Of Analyst Opinions | 5 |
| Open | 8.53 |
| Operating Cashflow | -16,009,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 201 614 3150 |
| Post Market Change | -0.09999943 |
| Post Market Change Percent | -1.1235892 |
| Post Market Price | 8.8 |
| Post Market Time | 1,776,465,968 |
| Previous Close | 8.35 |
| Price Hint | 2 |
| Price To Book | 12.41283 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.379 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.549999 |
| Regular Market Change Percent | 6.58682 |
| Regular Market Day High | 8.92 |
| Regular Market Day Low | 8.33 |
| Regular Market Day Range | 8.33 - 8.92 |
| Regular Market Open | 8.53 |
| Regular Market Previous Close | 8.35 |
| Regular Market Price | 8.9 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 92,572 |
| Return On Assets | -0.68501997 |
| Return On Equity | -1.88025 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 26,491,702 |
| Shares Percent Shares Out | 0.059499998 |
| Shares Short | 1,575,869 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,620,407 |
| Short Name | Nuvectis Pharma, Inc. |
| Short Percent Of Float | 0.1018 |
| Short Ratio | 25.17 |
| Source Interval | 15 |
| State | NJ |
| Symbol | NVCT |
| Target High Price | 20.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 16.8 |
| Target Median Price | 18.0 |
| Total Cash | 31,634,000 |
| Total Cash Per Share | 1.194 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.3449 |
| Two Hundred Day Average Change | 1.5550995 |
| Two Hundred Day Average Change Percent | 0.21172507 |
| Type Disp | Equity |
| Volume | 92,572 |
| Website | https://www.nuvectis.com |
| Zip | 7,024 |